Experience use of a non-invasive marker activity of inflammation in the colon in patients with colon polyps and ulcerative colitis

2015 ◽  
Vol 9 (1) ◽  
pp. 0-0
Author(s):  
Матюхин ◽  
A. Matyukhin ◽  
Никитин ◽  
A. Nikitin
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Process ◽  
Modern Method ◽  
Clinical Activity ◽  
Colon Polyps ◽  
Faecal Calprotectin ◽  
Non Invasive ◽  
Calprotectin Level ◽  
High Degree ◽  
Instrumental Methods

. The activity of a non-invasive marker of inflammation in the colon is used to evaluate the clinical, endoscopic and biological characteristics of ulcerative colitis and colon polyps. In this study, the authors studied the possibility of using non-invasive marker – a faecal calprotectin as a highly sensitive method in the activity of the inflammatory process in the colon. The study included 40 patients with ulcerative colitis and colon polyps, which a colonoscopy was performed. The concentration of calprotectin in stool samples was determined in all patients and was evaluated according to the clinical activity of the disease. A significant increase in the level of calprotectin in patients with colon polyps 42±5,6 µg/g wasn’t revealed. On the contrary, the concentration of a faecal calprotectin was significantly higher in patients with ulcerative colitis. This concentration increases in patients with a high degree of inflammatory activity and length of lesions of the mucous membrane of the colon. The concentration of calprotectin level correlates with the extent of lesion and activity of the inflam-matory process in the colon, but not with endoscopic activity of ulcerative colitis. The use of modern method of non-invasive diagnostic marker of the inflammatory process in the intestine allows to diagnose functional and organic pathologies of the colon without the supplementary instrumental methods.

Differential diagnosis of organic and functional pathologies of the gastrointestinal tract by using a non-invasive marker of activity

2015 ◽  
Vol 9 (2) ◽  
pp. 0-0
Author(s):  
Никитин ◽  
A. Nikitin ◽  
Матюхин ◽  
A. Matyukhin
Keyword(s):  
Ulcerative Colitis ◽  
Irritable Bowel Syndrome ◽  
Differential Diagnosis ◽  
Gastrointestinal Tract ◽  
Inflammatory Process ◽  
Clinical Symptoms ◽  
Clinical Activity ◽  
Faecal Calprotectin ◽  
Non Invasive ◽  
Irritable Bowel

An irritable bowel syndrome is a functional disorder of the gastrointestinal tract with impaired motor skills, absorbing function and permeability of the intestine. Clinical symptoms of the disease don’t allow the doctor to make a differential diagnosis without sophisticated research tools and prescribe treatment. This study was devoted the comparative evaluation of clinical activity and the level of calprotectin in patients with organic and functional pathologies of the gastrointestinal tract. The study included 40 patients with ulcerative colitis and irritable bowel syndrome with diarrhea. Colonoscopy with histological examination of biopsy specimens and determination of a faecal calprotectin was performed. The concentration of calprotectin in feces was determined in all patients and was evaluated according to the clinical disease activity, extent of injury and activity of the inflammatory process in the intestine. The concentration of calprotectin in patients with irritable bowel syndrome with diarrhea conformed to the value of 24.6±2.4 µg/g, which is significantly lower values, than in patients with ulcerative colitis. Application of non-invasive markers of the inflammatory process will allow the doctors to solve common problems in diagnosis, to improve the effectiveness of supplementary opportunities and prospects of further expansion of the indications for colonoscopy and other endoscopic research.

The significance of calprotectin for the evaluation of activity of inflammation in ulcerative colitis

2016 ◽  
Vol 94 (7) ◽  
pp. 540-543
Author(s):  
A. V. Nikitin ◽  
Anatoliy Andreevich Matyukhin ◽  
V. I. Mordasova ◽  
M. N. Latysheva
Keyword(s):  
Ulcerative Colitis ◽  
Medical Care ◽  
Screening Test ◽  
Faecal Calprotectin ◽  
Non Invasive ◽  
Quality Of Medical Care ◽  
Instrumental Methods

The combination of clinical and instrumental methods with non-invasive markers of ulcerative colitis allows to predict the incidence of this disease and optimize conditions and quality of medical care. To-day, the use of non-invasive markers is a topical issuesince itprovidesa most informative screening test for the high-accuracydetermination ofresidual faecal calprotectin.

scholarly journals P130 Faecal calprotectin is a reliable tool to assess endoscopic activity in ulcerative colitis except for short-extent proctitis

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S202-S202
Author(s):  
R Collin ◽  
R Minet-Quinard ◽  
L Blayac ◽  
L Manlay ◽  
B Pereira ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
False Negative ◽  
Vascular Pattern ◽  
Endoscopic Evaluation ◽  
Faecal Calprotectin ◽  
Factors Associated ◽  
Non Invasive ◽  
Reliable Tool ◽  
Mayo Score ◽  
Calprotectin Level

Abstract Background Faecal calprotectin (Fcal) is now considered a reliablebiomarker of endoscopic inflammatory activity in patients with ulcerative colitis (UC). However, this biomarker remains imperfect with some false negative in some clinical situations. We aimed to search for endoscopic factors associated with faecal calprotectin level in patients with UC and to identify situations in which this tool might be less efficient. Methods From a database collecting consecutively all the patients with IBD with at least one Fcal dosage in our centre between June 2016 and June 2018, we included all patients who had an endoscopic evaluation within the month before or after dosing without intervention therapeutic during this interval. Fcal level was measured by immuno-chemiluminescence in all patients. Results One hundred and thirty-four patients were included (E1 in 12 patients (9.0%), E2 in 69 patients (51.5%) and E3 in 53 of them (39.5%)). There was a significant correlation between the UCEIS score and Fcal level (r = 0.55, p > 0.001). Fcal level was significantly associated with endoscopic Mayo score with higher values in severe cases (Mayo 0: 32 [15.5–75.3], Mayo 1: 119 [48.0–634.0], Mayo 2: 773 [150.8–1965.0] and Mayo 3: 1200 [572.0–3717.5] μg/g; p < 0.01 for all comparisons). Using an ROC curve, we have defined the best CF thresholds to define an endoscopic Mayo> 1. The performances are presented in the Table 1. In the same way, 100 μg/g was the best Fcal threshold to define a remission endoscopic (endoscopic Mayo score = 0): sensitivity = 79.3% [66.6%–86.3%], specificity = 88.9% [65.3%–98.6%], PPV = 97.9% [92.5%–99.7%], VPN = 40% [24.9%–56.7%]. In multivariate analysis, endoscopic factors associated with the values of CF are: the UCEIS sub-score – vascular pattern (p = 0.001), the UCEIS sub-score – ulcerations (p = 0.013) and the extent of the disease (p = 0.009). CF level in patients with endoscopic Mayo 0 or 1 is lower in the case of low proctitis (<5 cm) than in the case of more extensive RCH (45.5 [19.5–90.5] vs. 214.5 [71.5–730], p < 0.001). While the values of CF were significantly correlated with UCEIS score in patients with proctitis >5 cm (ρ = 0.3665, p < 0.001), they were not low rectal (<5 cm) (ρ = 0.1571, p = 0.71). Conclusion CF is a reliable tool for indirect and non-invasive assessment of activity endoscopic inflammatory disease in UC. Fcal is mainly influenced by severity and extent of the lesions. Its use should be careful in case of proctitis under 5 cm, a situation in which its performances are more questionable.

scholarly journals Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab

2019 ◽  
Vol 12 ◽  
pp. 175628481986914
Author(s):  
Fernando Magro ◽  
Susana Lopes ◽  
Marco Silva ◽  
Rosa Coelho ◽  
Francisco Portela ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Therapeutic Response ◽  
Clinical Activity ◽  
Open Label ◽  
Faecal Calprotectin ◽  
Reactive Protein ◽  
Mayo Score ◽  
Histological Activity ◽  
Median Change ◽  
Multicentre Prospective Study

Background: Suppressor of Tumorigenicity 2 (ST2) is an IL33 receptor detected in the mucosa and serum of ulcerative colitis (UC) patients. We evaluated soluble ST2 (sST2) as a surrogate biomarker of disease outcome and therapeutic response, in moderate-to-severe UC patients treated with golimumab. Methods: We conducted an open-label single-arm multicentre prospective study. At screening/baseline, week 6 (W6) and week 16 (W16), clinical and endoscopic activity (total Mayo score), histologic activity (Geboes index) and biomarkers were evaluated. Results: From 38 patients, 34 (89.5%) completed W6 and 29 (76.3%) completed W16. Mean age (±SD) was 34.6 ± 12.6 years; 55.9% were female. At W16, 62.1% achieved clinical response. Patients with endoscopic activity at W6 ( n = 20) had higher baseline sST2 (median, 24.5 versus 18.7 ng/ml, p = 0.026) and no decrease from baseline (median change, 0.8 versus −2.7, p = 0.029). At W6, sST2 levels correlated with endoscopic activity ( rs = 0.45, p = 0.007) but not with histological activity ( rs = 0.25, p = 0.151). The best cut-offs for endoscopic activity were sST2 = 16.9 ng/ml (sensitivity = 85%; specificity = 71%) and faecal calprotectin (FC) = 353 μg/g (sensitivity = 90%, specificity = 67%). Patients with histological activity at W6 ( n = 27) had higher baseline ST2 levels (median, 23.0 versus 13.7 ng/ml, p = 0.035). sST2 did not correlate with FC or serum C-reactive protein. FC levels correlated with histological activity and baseline FC were higher when Geboes ⩾3.1 at W6. Conclusions: sST2 may be a surrogate biomarker of UC activity and therapeutic response as it correlates with endoscopic and clinical activity at W6 of golimumab treatment, and subjects with endoscopic and histological activity at W6 had higher baseline ST2 levels.

scholarly journals CLINICAL FORMS OF ULCERATIVE COLITIS AND THEIR FEATURES IN CHILDREN

2020 ◽  
Author(s):  
Денисова М. Ф. ◽  
Букулова Н. Ю.
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Process ◽  
Clinical Laboratory ◽  
Fecal Calprotectin ◽  
Clinical Activity ◽  
Clinical Forms ◽  
Γ Globulins ◽  
Endoscopic Characteristics ◽  
And Gender ◽  
The Relationship

This article presents frequency of occurrence of clinical forms of the disease depending on the localization and activity of the inflammatory process, their age and gender differences, risk factors and disease triggers, based on a retrospective analysis of 116 cases of children with ulcerative colitis at the age of 4-18 years. Comparative clinical, laboratory and endoscopic characteristics of total, segmental and distal colitis have been also analyzed. It was found that clinical activity of total colitis is characterized by more severe course of the disease, accompanied with systemic and local extraintestinal manifestations (OR = 4,504±0,506, p<0.05), more pronounced changes in hemo- and proteinogram parameters (p<0.05). Endoscopic criteria for differences in the clinical forms of ulcerative colitis are the presence of ulcers (OR = 9,667±0,645, p <0,05), erosions (OR = 3,569±0,429, p<0,05), contact bleeding (OR = 4,364± ,444, p< 0.05), changes in the vascular pattern (OR = 3,748±0,477, p<0.05). Correlation analysis of the relationship between clinical (PUCAI), endoscopic (Rachmilewitz index) and laboratory markers of the inflammatory process (leukocytes, platelets, erythrocyte sedimentation rate, γ-globulins, fecal calprotectin, hemoglobin) has been also performed, the criteria of which might be used to monitor the course of the disease and the effectiveness of therapy.

scholarly journals P063 Faecal calprotectin as a non-invasive treatment target to predict mucosal healing and histological remission in asymptomatic ulcerative colitis

2018 ◽  
Vol 12 (supplement_1) ◽  
pp. S124-S125
Author(s):  
A Correia Varela Almeida ◽  
J M Vázquez Morón ◽  
E Gómez Delgado ◽  
H Pallarés Manrique ◽  
A Talavera Fabuel ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Mucosal Healing ◽  
Invasive Treatment ◽  
Faecal Calprotectin ◽  
Treatment Target ◽  
Non Invasive ◽  
Histological Remission
Sign in / Sign up

Export Citation Format

Share Document